

# Mannitol Preserves the Viscoelastic Properties of Hyaluronic Acid in an In Vitro Model of Oxidative Stress

Thierry Conrozier · Pierre Mathieu · Marguerite Rinaudo

Received: April 22, 2014

© The Author(s) 2014. This article is published with open access at Springerlink.com

## ABSTRACT

**Introduction:** Viscosupplementation by intra-articular injection of hyaluronic acid (HA) is a widely used treatment for lower limb osteoarthritis. However, the injected HA is rapidly degraded by reactive oxygen species (ROS), limiting its time of intra-articular residence. Optimizing clinical effectiveness of viscosupplementation by reducing HA degradation in situ, and therefore increasing the time of contact with the diseased tissue, is a challenging research approach. Mannitol, a powerful ROS scavenger, is a good candidate for

this. The aim of this study was to compare in vitro the resistance to ROS-mediated degradation of two marketed viscosupplements (one linear and one cross-linked) to that of two novel viscosupplements combining HA and mannitol.

**Methods:** A HA viscosupplement at a concentration of 10 g/L (HA 1%), was compared to a HANOX-M, a novel viscosupplement made of a mixture of HA and mannitol. In a second experiment, Hylan G-F 20, a partially cross-linked viscosupplement, was compared to a HANOX-M-XL, a novel cross-linked viscosupplement made of a HA and mannitol (35 g/L). The four HA viscosupplements were subjected to oxidative stress generated by the addition of hydrogen peroxide ( $H_2O_2$ ) and their rheological behavior (elastic moduli  $[G']$ , viscous moduli  $[G'']$ , and complex viscosity  $[|\eta^*|]$ ) were compared before and after the oxidative stress exposure.

**Results:** The two viscosupplements not containing mannitol HA were rapidly degraded by  $H_2O_2$ , as demonstrated by the dramatic decrease of  $|\eta^*|$ . On the other hand, the rheological properties of HA containing mannitol were not substantially modified in the presence of  $H_2O_2$ .

---

**Electronic supplementary material** The online version of this article (doi:[10.1007/s40744-014-0001-8](https://doi.org/10.1007/s40744-014-0001-8)) contains supplementary material, which is available to authorized users.

---

T. Conrozier (✉)  
Service de Rhumatologie, Centre Hospitalier de  
Belfort-Montbéliard, Belfort, France  
e-mail: thierry\_conrozier@hotmail.fr;  
tconrozier@chbm.fr

P. Mathieu  
Rhumatologue, Chazelles-sur-Lyon, France

M. Rinaudo  
Biomaterials Applications, Grenoble, France

**Conclusion:** This in vitro study demonstrates that mixing mannitol with HA protects the viscosupplement from ROS-mediated degradation and might therefore increase its intra-articular residence time without substantially modifying its rheological behavior. This in vitro study has to be followed by clinical trials designed to assess whether the addition of mannitol to HA might improve the efficiency and/or the duration of action of viscosupplementation.

**Keywords:** Antioxidant; Hyaluronic acid; Hydrogen peroxide; Mannitol; Osteoarthritis; Reactive oxygen species; Rheology; Viscoelastic properties; Viscosupplementation

## INTRODUCTION

The hallmark of osteoarthritis (OA) is an increased degradation of the articular cartilage extracellular matrix (ECM) molecules, leading to progressive cartilage destruction, combined with several other joint tissue changes including bone remodeling (osteophyte formation, subchondral sclerosis, cyst formation), synovium low-grade inflammation, and frequently synovial fluid (SF) effusion [1].

Viscosupplementation by intra-articular injections of high molecular weight (HMW) hyaluronic acid (HA) is a widely used treatment for knee OA, aimed to restore the rheological homeostasis of the SF and to precipitate a restoration of normal HA metabolism [2, 3]. HA biologic functions depend on interactions with specific binding proteins called hyaladherins that modify the conformation of HA such as the cell surface hyaluronan receptor (CD44), HA-mediated motility (RHAMM), and hyaluronan-binding proteins of the ECM. Indeed, SF is a viscoelastic system consisting in a complex of

HA and proteins constituting a physical 3D-network [4–7]. HA is an anionic polyelectrolyte, constituted of alternating units of *N*-acetylglucosamine and *D*-glucuronic acid molecules. In healthy SF the polysaccharide chain can be up to 12,000 disaccharide units and has an average MW of 4–6 million Da. HA is produced in synovial joints by hyalocytes located in the synovial membrane and is released into the SF [3]. It plays a major role in lubrication, shock absorption, and viscoelastic behavior of the SF [3] involving entanglements in HA and proteins/HA association based mainly on electrostatic interactions. This viscoelastic behavior, which is directly related to both MW and concentration of HA [8], allows the HA 3D network to adapt to the mechanical stress applied. At low shear, such as occurs during a slow movement, the linear chains of HA align slowly in the direction of flow and behave like a viscous fluid. When the joint is subjected to fast impact (i.e., running or jumping) HA molecules do not have time enough to realign and exhibit elastic behavior, allowing shock absorption. This change in behavior is called viscoelastic behavior based on the temporary network formed by chain entanglements (as observed in dynamic experiments) and usually corresponds to a non-Newtonian behavior in flow experiments.

In OA joints, SF viscoelasticity, and consequently ability to protect cartilage, are dramatically lowered when compared with healthy SF as a result of a decrease of both HA MW and concentration [2].

Viscosupplementation effect is not fully clarified and is probably due to several mechanisms such as promotion of endogenous HMW HA production [9], interaction with pain receptors, and various anti-inflammatory effects [10–16].

There are now more than 25 commercial viscosupplement formulations available

worldwide from different manufacturers. These products widely vary in their MW, concentration, volume, indication, residence time into the joint [17–19], and recommended dosing regimens, ranging from one to five injections at weekly intervals. Despite the long history of this therapy and its inclusion in several guidelines for the management of OA subject to certain conditions [20–26], the use of viscosupplementation in OA remains a topic for debate regarding treatment efficacy and safety, ideal dosing regimen, cost-efficacy, differences between commercial preparations, and predictors of clinical response [27–30]. These discrepancies may originate from differences in efficacy between the studied products, varying in concentration, MW, and molecular cross-linkage [20]. Indeed, the HA injected into the joint is rapidly degraded, limiting the time of intra-articular residence from a few days for linear molecules [17] to a few weeks for the solutions of cross-linked HA [18, 19]. Among the many pathogenic mechanisms contributing to HA degradation, reactive oxygen species (ROS) derivatives play a major role [31, 32]. Then OA is a degenerative joint disease of multifactorial origin in the pathogenesis of which ROS play a deleterious effect [33]. It has been shown that interleukin-1 $\beta$  (IL-1 $\beta$ ) activates the production by the chondrocytes of large amounts of ROS which are themselves involved in the production and/or the activation of collagenase matrix metalloproteinase-1 and in the phenomena of chondrocyte apoptosis [34]. In addition to their effect on the degradation of the ECM, ROS are directly involved in the mechanisms of degradation of HA. Optimizing clinical effectiveness of viscosupplementation by reducing HA degradation in situ, and therefore increasing the time of contact with the diseased tissue [35], is a challenging research approach. We [36] and others [32] have

previously shown that the addition of mannitol (a polyol well known for its ROS-scavenging properties) with HA, protects the latter to ROS-mediated degradation and therefore may increase the injected HA residence time into the joint.

The aim of the present study was to compare in vitro the resistance to ROS-mediated-degradation of two marketed viscosupplements (one linear and one cross-linked) to that of two novel viscosupplements combining HA and mannitol.

## METHODS

This article does not contain any studies with human or animal subjects performed by any of the authors.

### Viscosupplements to be Assessed

In the first experiment, a HA viscosupplement with an average MW of 800 kDa at a concentration of 10 g/L [HA 1%] (Go-on<sup>®</sup>; Rottapharm SpA, Monza, Italy), was compared to a HANOX-M (HAppyVisc<sup>®</sup>; LABRHA, Lyon, France), a novel viscosupplement made of a mixture of HA (15.5 g/L, average MW 1 MDa) and mannitol (35 g/L). Both were of biofermentation origin and were not cross-linked.

In the second experiment, Hylan G-F 20, a partially cross-linked viscosupplement, obtained from cockscomb extraction, at a HA concentration of 8 g/L with a stated MW of 6 MDa (Synvisc<sup>®</sup>; Sanofi-Aventis, France) was compared to a HANOX-M-XL (HAppyCross<sup>®</sup>; LABRHA), a novel cross-linked viscosupplement also made of a mixture of a non-animal origin HA (16 g/L) and mannitol (35 g/L).

The average MW of each linear HA was determined using steric exclusion

chromatography using a chromatograph (Waters® Alliance® GPC/V 2000; Waters Corporation, Milford, MA, USA) equipped with three detectors in line (26). The injected concentration was 2 g/L, with an injection volume of 100 µL using two columns in series (OHpak® 805 and 806; Shodex, Munich, Germany). All samples were filtered through a membrane with pores of 0.2 µm (Cellulose Acetate Membrane Filter; Sartorius, Surrey, UK) prior to injection in order to retain any aggregates. The eluent used was 0.1 M NaNO<sub>3</sub> at an elution temperature of 30 °C and a flow rate of 0.5 mL/min.

### Induction of Oxidative Stress

Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) application is a well-known method to degrade polysaccharides through a radical mechanism [37]. The 4 HA viscosupplements mentioned above were subjected to oxidative stress generated by the addition of H<sub>2</sub>O<sub>2</sub> (30%; Carl Roth GmbH & Co. KG, Lauterbourg, Germany) at a final concentration of 2.7% and/or 5.4% (v/v). For that purpose, the commercial samples were added of H<sub>2</sub>O<sub>2</sub> in a ratio 10:1 and stirred before being placed rapidly on the rheometer (delay time between addition of H<sub>2</sub>O<sub>2</sub> and first measurement was 2 min).

### Rheological Assessment

The rheological properties were measured using a cone-plate rheometer (ARES-G2 Rheometer; TA Instruments, New Castle, DE, USA) at 25 °C on the different solutions as a function of the oxidative stress time at room temperature. The dynamic experiments were carried out in the region of linear viscoelasticity, where the  $G'$  elastic and  $G''$  viscous moduli are independent of the applied frequency. The dynamic moduli expressed in Pa


( $G'$ , the elastic contribution, and  $G''$ , the storage contribution) and the complex viscosity ( $|\eta^*|$ ) were taken at the angular frequency ( $\omega$ ) of 1 Hz.

## RESULTS


The two viscosupplements not containing mannitol HA were rapidly degraded by hydrogen peroxide, as demonstrated by the dramatic decrease of the complex viscosity ( $|\eta^*|$ ). On the other hand, the rheological properties of the HA solutions containing 35 g/L of mannitol were not substantially modified in the presence of H<sub>2</sub>O<sub>2</sub> over a period of 15 or 30 min. The resistance to oxidative stress was much better for the cross-linked (HANOX-M-XL) than for the non-cross-linked (HANOX-M) HA containing mannitol, the cross-linking being the only difference between them (same origin, and same HA and mannitol concentrations). Likewise, at baseline, HANOX-M was much more viscous than HA 1%, because of its higher MW (average MW 1.2 MDa versus 789 kDa) and concentration (15.5 g/L versus 10 g/L).

Figure 1 shows the rheological behaviors of the two linear viscosupplements. It clearly demonstrates that the presence of mannitol in HANOX-M stabilizes HA against oxidative degradation. Conversely, it shows that the elastic modulus ( $G'$ ) of HA 1% solution was particularly decreased. The values of rheological parameters (elastic and viscous moduli, complex viscosity) taken after 15 min are represented in Fig. 2. This histogram is very indicative of the benefit of mannitol on HA stability after H<sub>2</sub>O<sub>2</sub> exposure.

Under the same experimental conditions, the kinetics of degradation of the two cross-linked viscosupplements was compared (see Figs. 3, 4). The influence of mannitol is again




**Fig. 1** Elastic ( $G'$ ) and storage ( $G''$ ) moduli at 1 Hz of hyaluronic acid (HA) solutions as a function of oxidative degradation time on linear hyaluronans. *Filled triangle*  $G'$  (Pa) *open triangle*  $G''$  (Pa) on HANOX-M; *filled square*  $G'$  (Pa) *open square*  $G''$  (Pa) on HA 1%




**Fig. 2** Decrease (%) of elastic ( $G'$ ) and viscous ( $G''$ ) moduli and complex viscosity ( $|\eta^*|$ ) after 15 min of oxidative stress by hydrogen peroxide. Comparison of two linear non cross-linked viscosupplements: HANOX-M and hyaluronic acid (HA) 1%

obvious. Nevertheless, the level of the elastic modulus ( $G'$ ) of HANOX-M-XL, which is much higher than that of Hylan G-F 20, indicates that its degree of cross-linkage is higher than that of Hylan G-F 20. The better resistance to

degradation of HANOX-M-XL is likely due to both mannitol and its high level of cross-linkage. Figure 4 represents the rheological parameters after 15 min of oxidative degradation.



**Fig. 3** Elastic ( $G'$ ) and storage ( $G''$ ) moduli at 1 Hz of hyaluronic acid (HA) solutions as a function of oxidative degradation time on crosslinked hyaluronans. *Filled triangle*  $G'$  (Pa) open triangle  $G'$  (Pa) on HANOX-M-XL; *filled square*  $G''$  (Pa) open square  $G''$  (Pa) on Hylan G-F 20



**Fig. 4** Decrease (%) of elastic ( $G'$ ) and viscous ( $G''$ ) moduli and complex viscosity ( $|\eta^*|$ ) after 15 min of oxidative stress by hydrogen peroxide. Comparison of two cross-linked viscosupplements: HANOX-M-XL and Hylan G-F 20

## DISCUSSION

This in vitro study, using a powerful model of oxidative stress, shows that the addition of high concentration of mannitol (35 g/L) to HA protects HA from degradation. Mannitol ( $C_6H_{14}O_6$ ) is a polyol well known for its properties as a ROS scavenger. The beneficial

effect related to its antioxidant power towards the rich reactive hydroxyl function has been shown in various diseases [38–41].

In viscosupplementation, the rationale of its combination with HA is legitimate: When administered intra-articularly, HA macromolecules of the viscosupplement, containing many OH groups, react with ROS,

resulting in the rupture of the macromolecular chains and accelerated degradation by radical mechanism [31]. This rapid depolymerization of HA is the main cause for the short intra-articular half-life of viscosupplements made of non-cross-linked HA, cross-linking being another way to protect HA from degradation by ROS [18, 19]. The chemical characteristics of mannitol make it an antioxidant of choice in combination with HA. As with HA, mannitol has a very good safety profile, as demonstrated by animal tests showing that it was non-cytotoxic, non-genotoxic, non-carcinogenic, and non-mutagenic, even at high doses [42]. In humans, mannitol is widely used per os and by intravenous injection at very high concentrations, including hyperosmolar concentrations [43]. Its resistance to heat also permits sterilization by autoclaving, unlike other antioxidants that are thermolabile (e.g., polyphenols, vitamin C). Furthermore, mannitol does not increase the ionic strength of the medium and thus does not significantly alter the rheological behavior of the HA, and is hydrosoluble, unlike antioxidants such as vitamin E or betacarotene [44]. Two open-label clinical trials assessing viscosupplements containing antioxidants (mannitol 5 g/L [45] or its isomer sorbitol 40 g/L [46]) in patients suffering from knee OA have been recently published. In both, safety was similar to that of conventional viscosupplements not containing antioxidant, and none of them has revealed any serious or unexpected adverse effects. In the absence of a control group, the efficacy cannot be conclusively assessed; however, the published results strongly suggested the beneficial effects of the treatments on pain and function.

Our data also suggested that HA cross-linking, high MW and high concentration may play a role in the improved resistance to oxidative stress and are other effective ways to protect HA from degradation.

## CONCLUSION

In summary, this in vitro study demonstrates that mixing high concentrations of mannitol with HA, protects the viscosupplement from ROS-mediated degradation and might therefore increase the intra-articular residence time of the gel without substantially modifying its rheological behavior. Thereby, the combination of HA and mannitol might be a simple mean to improve the efficiency and/or the duration of action of joint viscosupplementation. These in vitro results fully justify the in vivo studies already in progress with both HANOX-M and HANOX-M-XL whose aims are to confirm or refute this exciting hypothesis and to assess the effectiveness and safety of this new promising association on large samples of patients.

## ACKNOWLEDGMENTS

The study has been sponsored by LABRHA (Laboratoire de Rhumatologie Appliquée, 19 place Tolozan, 69001, Lyon, France). The authors thank the Laboratory Rhéologie et Procédés of Grenoble University for their technical contribution. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. The study has been sponsored by LABRHA (Laboratoire de Rhumatologie Appliquée, 19 place Tolozan, 69001, Lyon, France).

**Conflict of interest.** Thierry Conrozier has received fees of consultant from LABRHA of

which he is a regular consultant and member of the scientific board. Marguerite Rinaudio has received honoraria from LABRHA for conducting the study. Pierre Mathieu does not declare any conflict of interest.

**Compliance with ethics guidelines.** This article does not contain any studies with human or animal subjects performed by any of the authors.

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

## REFERENCES

- Pelletier JP, Martel-Pelletier J. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. *J Rheumatol*. 1993;20(suppl 39):19–23.
- Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. *J Rheumatol Suppl*. 1993;9:3–9.
- Balazs EA. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. *Surg Technol Int*. 2004;12:278–89.
- Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. *Biorheology*. 2007;44:59–74.
- Mathieu P, Conrozier T, Vignon E, Rozand Y, Rinaudo M. Rheologic behavior of osteoarthritic synovial fluid after addition of hyaluronic acid: a pilot study. *Clin Orthop Relat Res*. 2009;467:3002–9.
- Rinaudo M, Rozand Y, Mathieu P, Conrozier T. Role of different pre-treatments on composition and rheology of synovial fluids. *Polymers*. 2009;1:16–34.
- Conrozier T, Mathieu P, Vignon E, Piperno M, Rinaudo M. Differences in the osteoarthritic synovial fluid composition and rheology between patients with or without flare: a pilot study. *Clin Exp Rheumatol*. 2012;30:729–34.
- Milas M, Rinaudo M. Characterization and properties of hyaluronic acid (hyaluronan). In: Dimitriu S, editor. *Polysaccharides: structural diversity and functional versatility*. New York, NY: Marcel Dekker; 2004. p. 535–49.
- Bagga H, Burkhardt D, Sambrook P, March L. Long term effects of intra-articular hyaluronan on synovial fluid in osteoarthritis of the knee. *J Rheumatol*. 2006;33:946–50.
- Greenberg DD, Stoker A, Kane S, Cockrell M, Cook JL. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. *Osteoarthr Cartil*. 1993;1:97–103.
- Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. *Osteoarthr Cartil*. 2006;14:1237–47.
- Li P, Raitcheva D, Hawes M, et al. Hylan G-F 20 maintains cartilage integrity and decreases osteophyte formation in osteoarthritis through both anabolic and anti-catabolic mechanisms. *Osteoarthr Cartil*. 2012;20:1336–46.
- Li J, Gorski DJ, Anemaet W, et al. Hyaluronan injection in murine osteoarthritis prevents TGFbeta 1-induced synovial neovascularization and fibrosis and maintains articular cartilage integrity by a CD44-dependent mechanism. *Arthritis Res Ther*. 2012;14:R151.
- Waddell DD, Kolomytkin OV, Dunn S, Marino AA. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. *Clin Orthop Relat Res*. 2007;465:241–8.
- Yasuda T. Hyaluronan inhibits prostaglandin E2 production via CD44 in U937 human macrophages. *Tohoku J Exp Med*. 2010;220:229–35.
- Boettger MK, Kümmel D, Harrison A, Schaible HG. Evaluation of long-term antinociceptive properties of stabilized hyaluronic acid preparation (NASHA) in an animal model of repetitive joint pain. *Arthritis Res Ther*. 2011;13:R110.
- Lindenhayn K, Heilmann HH, Niederhausen T, Walther HU, Pohlenz K. Elimination of tritium-labelled hyaluronic acid from normal and osteoarthritic rabbit knee joints. *Eur J Clin Chem Clin Biochem*. 1997;35:355–63.
- Lindqvist U, Tolmachev V, Kairemo K, Aström G, Jonsson E, Lundqvist H. Elimination of stabilised



- hyaluronan from the knee joint in healthy men. *Clin Pharmacokinet.* 2002;4:603–13.
19. Larsen NE, Dursema HD, Pollak CT, Skrabut EM. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. *J Biomed Mater Res Part B.* 2012;100B:457–62.
  20. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev.* 2006;2:CD005321.
  21. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res.* 2012;64:465–74.
  22. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis.* 2005;64:669–81.
  23. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). *Ann Rheum Dis.* 2003;62:1145–55.
  24. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence based, expert consensus guidelines. *Osteoarthr Cartil.* 2008;16:137–62.
  25. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthr Cartil.* 2010;18:476–99.
  26. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). *Ann Rheum Dis.* 2000;59:936–44.
  27. Miller LE, Block JE. US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials. *Clin Med Insights Arthritis Musculoskelet Disord.* 2013;6:57–63.
  28. Bannuru RR, Vaysbrot EE, Sullivan MC, McAlindon TE. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. *Semin Arthritis Rheum.* 2014;43:593–9.
  29. Rutjes AW, Jüni P, da Costa BR, Trelle S, Nuesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. *Ann Intern Med.* 2012;157:180–91.
  30. Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis: a systematic review and meta-analysis with emphasis on the efficacy of different products. *Bio Drugs.* 2012;26:257–68.
  31. Stern R, Kogan G, Jedrzejewski MJ, Soltés L. The many ways to cleave hyaluronan. *Biotechnol Adv.* 2007;25:537–57.
  32. Mendoza G, Alvarez AI, Pulido MM, et al. Inhibitory effects of different antioxidants on hyaluronan depolymerization. *Carbohydr Res.* 2007;342:96–102.
  33. Grange L, Nguyen MV, Lardy B, et al. NAD(P)H oxidase activity of Nox4 in chondrocytes is both inducible and involved in collagenase expression. *Antioxid Redox Signal.* 2006;8:1485–96.
  34. Rousset F, Nguyen MV, Grange L, Morel F, Lardy B. Heme oxygenase-1 regulates matrix metalloproteinase MMP-1 secretion and chondrocyte cell death via Nox4 NADPH oxidase activity in chondrocytes. *PLoS One.* 2013;20(8):e66478.
  35. Chevalier X. Intraarticular treatments for osteoarthritis: new perspectives. *Curr Drug Targets.* 2010;11:546–60.
  36. Conrozier T, Lardy B, Rinaudo M. Effect of high concentrations of mannitol on the stability of hyaluronan in an oxidative stress model induced by xanthine/xanthine oxidase. *Osteoarthr Cartil.* 2014;22:S478.
  37. Soltés L, Kogan G, Stankovska M, et al. Degradation of high-molar-mass hyaluronan and characterization of fragments. *Biomacromolecules.* 2007;8:2697–705.
  38. Belda JI, Artola A, García-Manzanares MD, et al. Hyaluronic acid combined with mannitol to improve protection against free-radical endothelial damage: experimental model. *J Cataract Refract Surg.* 2005;31:1213–8.
  39. Magovern GJ Jr, Bolling SF, Casale AS, Bulkley BH, Gardner TJ. The mechanism of mannitol in reducing ischemic injury: hyperosmolarity or

- 
- hydroxyl scavenger? *Circulation*. 1984;70(suppl1): 91–5.
40. Suzuki J, Imaizumi S, Kayama T, Yoshimoto T. Chemiluminescence in hypoxic brain—the second report: cerebral protective effect of mannitol, vitamin E and glucocorticoid. *Stroke*. 1985;16:695–700.
41. Fu W, Jiao X. The effect of mannitol and anisodim on the prevention of free radical injury to post-ischemia flaps: an experimental study. *Br J Plast Surg*. 1995;48:218–21.
42. Mannitol: INCHEM International program for Chemical safety (IPCS): <http://www.inchem.org/documents/jecfa/jecmono/v21je10.htm> (2014). Accessed June 6 2014.
43. VIDAL: [http://www.vidal.fr/recherche/index/q:mannitol/sorbitol/classe\\_therapeutique](http://www.vidal.fr/recherche/index/q:mannitol/sorbitol/classe_therapeutique) (2014). Accessed June 6 2014.
44. Sies H. Relationship between free radicals and vitamins: an overview. *Int J Vitam Nutr Res Suppl*. 1989;30:215–23.
45. Borrás-Verdera A, Calcedo-Bernal V, Ojeda-Levenfeld J, Clavel-Sainz C. Efficacy and safety of a single intra-articular injection of 2% hyaluronic acid plus mannitol in knee osteoarthritis over a 6-month period. *Rev Esp Cir Ortop Traumatol*. 2012;56:274–80.
46. Heisel J, Kipshoven C. Safety and efficacy findings from a non-interventional study of a new hyaluronic acid/sorbitol formulation (GO-ON matrix) for intra-articular injection to relieve pain and disability in osteoarthritis patients. *Drug Res*. 2013;63:445–9.